BresaGen signs two new contracts
Tuesday, 02 August, 2005
Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
The first is with Irish based Opsona Therapeutics, which will use BresaGen to progress process development of its pre-clinical immunomodulator, OPN-201. The second contract is with US firm Pepgen Corporation, which first partnered with BresaGen in 2004, to develop a process for Pepgen to produce a novel interferon alpha analog, Neoferon.
Under the contract, BresaGen will further develop the E. coli-based process and produce GLP recombinant protein.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
